RFL

Rafael Holdings Inc

Add to Watchlist

Advanced Chart

1.740

+0.010(+0.580%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.740

Open

1.740

VWAP

1.73

Vol

4.24K

Mkt Cap

55.44M

Low

1.690

Amount

7.32K

EV/EBITDA(TTM)

Total Shares

24.57M

12.69M

EV/OCF(TTM)

P/S(TTM)

58.75

Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel.

Valuation Metrics

The current forward P/E ratio for Rafael Holdings Inc (RFL.N) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Rafael Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q2

YoY :

+13.24%

77.00K

Total Revenue

FY2025Q2

YoY :

+14.19%

-3.59M

Operating Profit

FY2025Q2

YoY :

-187.18%

-5.33M

Net Income after Tax

FY2025Q2

YoY :

-176.00%

-0.19

EPS - Diluted

FY2025Q2

YoY :

-8.54%

-2.32M

Free Cash Flow

FY2025Q2

YoY :

-166.23%

-66.23

Gross Profit Margin - %

FY2025Q2

YoY :

-54.78%

-1.23K

FCF Margin - %

FY2025Q2

YoY :

-179.68%

-6.92K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RFL News & Events

Events Timeline

2024-12-11 (ET)

2024-12-11

06:02:47

Rafael Holdings reports Q1 EPS (37c) vs (15c) last year

2024-07-15 (ET)

2024-07-15

03:35:02

Rafael Holdings, Cyclo Therapeutics enter merger agreement

News

5.0

04-24Newsfilter

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

9.5

03-13Newsfilter

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

4.5

01-29NASDAQ.COM

Wednesday Sector Laggards: Real Estate, Consumer Services